Overview

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Status:
Active, not recruiting

Trial end date:
2023-08-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

AbbVie

Treatments:

BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Elotuzumab
Lenalidomide
Nivolumab
Pomalidomide